Tagged with CCE

Spain Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19 treatment, and the reimbursement challenges faced by rare disease players in Spain. Moreover, De Mora highlights Sobi’s vast clinical trials…

Italy   In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s third largest in Europe and sixth largest globally. Giese also touches on ensuring the affiliate’s product launch readiness, consistently increasing…

Italy Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in the early studies of remdesivir as a treatment against severe COVID-19 disease; how Gilead is working to eliminate viral Hepatitis…

Denmark Servier’s Estève Speranza outlines the rationale behind the French group’s reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics’ relevance to Servier as an innovation hub and home to its antibody centre of excellence.   Servier is actively looking…

Global On the 100th anniversary of the development of insulin, regular PharmaBoardroom contributor Brendan Shaw* examines the shocking global disparities in access to the lifesaving drug, but does not point the finger of blame at the pharmaceutical industry. Instead, Shaw highlights the high barriers of entry that dissuade these companies from…

Saudi Arabia After almost two decades with MSD, Ashraf Mallak, managing director for the company in the GCC region, dives into the often-overlooked healthcare capabilities of the Gulf countries, including the fact that certain products approved by the US FDA can sometimes be available in the region in as little as one…

Europe In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global market access & pricing strategic planning at Merck Group, casts his eye across Europe to assess how sustainability criteria are…

Denmark Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through the COVID-19 pandemic, the evolving access landscape for the company’s next-generation diabetes and obesity treatments, and why Denmark – despite…

China The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval designations have been awarded since 2015. Elsewhere, Pfizer is utilising drone technology to promote health education in remote areas and…

UAE Amgen MEA’s Mohamed Nasser* examines the current pharma commercialisation model, posits how the entire healthcare ecosystem’s rapid and effective response to COVID-19 could be replicable in other disease areas, and makes his predictions for the industry’s future direction.   Probably more than at any other time in history, the last…

Denmark Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the…

China The following is an overview from Accestra Consulting* of Part 2 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including an overview of administrative drug approvals and fast track review pathways by CDE.   Abstract Despite severe challenges from the COVID-19 pandemic, the Center for Drug Evaluation (CDE) of…